Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Oncology boards > Gyn Onc > Flashcards

Gyn Onc Flashcards

(78 cards)

Start Studying
1
Q

Management of early stage cervical cancer in general

A
  • Early stage cervical cancer.
    Upfront surgery (cervical conization vs. modified radical vs. radial hysterectomy depending on stage)
  • ***Adjuvant chemoradiation if path indicates intermediate or high-risk of recurrence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Surgical management of stage I cervical cancer

A

IF IA1, conization w/ no further management if margins negative
IF IA2,
modified radical hysterectomy (removal of uterus, cervix, upper ¼ of vagina, and paramteria)
simple hysterectomy w/ lymphadenectomy (can get away with simple hysterectomy)
IF IB1, radical hysterectomy w/ lymphadenectomy
IF IB2, radical hysterectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

First line for MMR deficient advanced endometrial

A

carbo/taxol/durvalumab w/ maintenance durvalumab until progression (DUO-E - PFS HR 0.42 in dMMR, OS immature)
*or dostarlimab w/ maintenace dostarlimab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Size threshold for surgery vs. CRT

A

4 cm (greater than 4 cm requires CRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CRT for cervical

A

weekly cisplatin w/ EBRT + brachytherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Indications for adjuvant chemoradiation in localized cervical

A
  • positive margins
  • node positive
  • parametrial invasion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Metastatic cervical mgmt

A

IF PD-L1 positive, platinum/carboplatin + paclitaxel + pembro +/- avastin
IF PD-l1 negative, platinum/taxol and bev

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

endometrial cancer presentation

A
  • pelvic pain
  • change in bowel habits
    *vaginal bleeding
  • discharge
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

endometrial cancer RF’s

A
  • obesity
  • HRT
  • tamoxifen
  • older age
  • infertility
    *endometrial hyperplasia
    *PCOS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Management of complex atypical hyperplasia

A

hysterectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lynch recommended endometrial cancer screening

A
  • transvaginal US annually starting at age 30
    *Risk reducing hysterectomy with BSO at 35 or after completing childbearing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

endometroid significance with endometrial

A
  • bread and butter, more common endometrial cancer
  • nonendometroid is higher risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Uterine serous cancer significance

A
  • aggressive, “serious”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Stage 1A endometrial management in woman wishing to preserve fertility

A
  • IF G1-2, hormone therapy with medrestol (oral progestin) can be used to preserve fertility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stage II endometrial mgmt

A

upfront surgery / adjuvant full pelvic EBRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stage III-IV endometrial mgmt

A
  • upfront surgery
  • adjuvant chemo
    *CRT also an option followed by chemo for Stage III
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

clear cell significance in endometrial

A
  • aggressively behaving, requires systemic therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

serous HER2+ endometrial cancer mgmt

A
  • add herceptin to carbo/taxol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

recurrent metastatic endometrial mgmt

A

IF treatment free interval of >6 months, retreat with carbo/taxol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Systemic therapy for uterine carcinosarcoma

A

ifosfamide or platinum-based therapy or taxol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

low grade endometrial stromal sarcoma mgmt

A
  • hormonal therapy medregstrol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

leiomyosarcoma mgmt

A

surgery if resectable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

stage IB cervical cancer mgmt

A

surgery with adjuvant brachytherapy (not full pelvic EBRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

ovarian cancer presentation

A
  • bloating
  • pelvic or abdominal pain
  • early satiety
  • urinary symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
ovarian cancer RF's
- obesity - estrogen exposure (later pregnancy after age 35) -
26
When germline BRCA testing is indicated in ovarian
All high grade ovarian
27
Ovarian cancer biomarker
CA-125
28
Stage I ovarian cancer mgmt
IF wishing to preserve fertility, salpingo-oophorectomy
29
general management of ovarian
upfront cytoreductive surgery w/ salpingo-oophorectomy and hysterectomy w/ adjuvant chemo
30
management of ovarian in nonsurgical patient
upfront systemic therapy
31
When adjuvant chemo is indicated in ovarian
1) Stage IC or higher (positive ascites or peritoneal washings) 2) G3 3) clear cell histology
32
Role of maintenance in ovarian
*Essentially PARP + avastin for anyone regardless of BRCA status if high risk for recurrence *PARP if not high risk for recurrence *So PARP maintenance for all and avastin if high risk for recurrence
33
niraparib SE
thrombocytopenia
34
Recurrent metastatic ovarian management
IF platinum sensitive, carbo/taxol +/- bev *second cytoreductive surgery if possible IF platinum resistant, liposomal doxorubicin + avastin IF no trial, alternative chemo - docetaxel, pemetrexed, doxorubicin
35
sensitivity to immunotherapy in ovarian
- not very effective
36
serous ovarian low grade management
- AI - MEK inhibitors
37
mucinous ovarian cancer mgmt
- GI regimens (platinum resistant), eg. mFOLFOX
38
ovarian dysgerminoma mgmt
- analogous to seminoma (BEP)
39
ovarian yolk sac (endodermal sinus) of ovary 1) characteristic path finding 2) mgmt
- schiller duval bodies - adjuvant BEP
40
immature teratoma of ovary mgmt
- adjuvant BEP
41
granulosa cell tumor of ovary of mgmt
- upfront surgery - BEP
42
sertoli-leydig tumor of ovary 1) presentation 2) mgmt
1) virilization (testosterone producing - opposite of male sertoli-leydig) 2) surgery w/ adjuvant BEP
43
Ethnicity with highest rising rate of endometrial cancer
Black
44
endometrial cancer RF's
obesity tamoxifen Unopposed estrogen therapy infertility *PCOS (increased estrogen production) Estrogen-producing ovarian tumors
45
Lynch genes mutated in majority of endometrial cancer pts
MLH1 + MSH2
46
Indication for MSI/MMR in endometrial cancer patients
All patients (universal screening)
47
Management of endometrial complex atypia
- treated as malignancy (high percentage have coexisting adenocarcinoma)
48
Management of endometrial in patients who aren't surgical candidates
XRT
49
Adjuvant management stage I endometrial management
- indicated for high grade disease - Brachytherapy vs. radiotherapy depending on depth of invasion (full pelvic if deep invasion)
50
Stage III endometrial mgmt
- cytoreductive surgery - adjuvant chemo +/- XRT
51
Management of endometrial with isolated vaginal/pelvic recurrence
XRT
52
Later line for endometrial post chemo
Lenvatinib + pembro
53
When VEGF addition is indicated in endometrial
p53 mutation in recurrent metastatic disease
54
Targetable mutation for first line endometrial
HER2 for Serous endometrial
55
Localized carcinosarcoma mgmt
Surgery with adjuvant carbo/taxol (noninferior to ifosfamide and better tolerated)
56
Management of endometrial stromal sarcoma
Hormonal therapy (megestrol acetate) - hormone sensitive
57
Gyn malignancy assocaited with diethylstilbestrol (DES) exposure in utero
clear cell adenocarcinoma of the vagina and cervix
58
Preferred firstline systemic therapy for low grade endometrial stromal sarcoma
- AI
59
Olaparib SE to know
pneumonitis
60
Rucaparib SE to know
hepatotoxic
61
Management of ovarian cancer pt in surveillance with rising CA 125
- PET or CT
62
Components of surgical staging for ovarian cancer
- omentectomy, peritoneal biopsies, + lymph node sampling
63
Molecular profiling of endometrial
- MSI/MMR *HER2
64
Status of HER2 in endometral
Added to systemic therapy in first line metastatic setting if HER2 positive
65
Management of stage II cervical cancer (extension beyond the uterus)
Concurrent chemoradiation (w/ EBRT), followed by brachytherapy
66
First line for low risk gestational trophoblastic neoplasm/choriocarcinoma
- single agent chemo with methotrexate or dactinomycin
67
first line for metastati uterine leiomyosarcoma
gemcitabine + docetaxel Doxorubicine + trabectedin (Preferred)
68
1) RF's for ovarian cancer 2) protective factor
1) Nulliparity and early menarche 2) OCP's
68
Cervical cancer screening
High risk HPV test q 5 yrs (preferred) starting at age 25 - HPV + cytology cotesting q 5 years also an option
69
Management of locally advanced small cell carcinoma of the cervix
- CRT with cisplatin and etoposide, followed by 2 additional cycles of cisplatin/etoposide *essentially the same as small cell of lung
70
Management of metastatic cervical with peritoneal carcinomatosis
- intraperitoneal cisplatin/taxol + IV taxol
71
Drug approved for ovarian with tumors expressing high levels of FOLR1
mivretuximab soravtansine
72
Tumor mutational profiling required for metastatic cervical cancer
PD-L1 (IO added to chemo for PD-L1 positive)
73
Gene mutation to know for granulosa cell tumors
FOXL2
74
Initial management of cervical cancer with pelvic wall extension and hydronephrosis
Concurrent CRT w/ platinum chemo followed by brachytherapy
75
Stage IA dysgerminoma management
Observation
76
Minimally invasive/robotic vs. open hysterectomy for small cervical tumors
open (minimally invasive associated with lower OS)
77
Recurrent metastatic cervical cancer management
same as de novo, platinum sensitivity doesn't apply (CONFIRM)

Oncology boards (41 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions